A sustained-release drug-delivery system of synthetic prostacyclin agonist, ONO-1301SR: a new reagent to enhance cardiac tissue salvage and/or regeneration in the damaged heart
详细信息 查看全文
- 作者：Satsuki Fukushima ; Shigeru Miyagawa ; Yoshiki Sakai ; Yoshiki Sawa
- 关键词：Prostacyclin agonist ; Surgical regeneration therapy ; Drug delivery system ; Translational research ; Preclinical studies
- 刊名：Heart Failure Reviews
- 出版年：2015
- 出版时间：July 2015
- 年：2015
- 卷：20
- 期：4
- 页码：401-413
- 全文大小：869 KB
- 参考文献：1.Felker GM, Shaw LK, O鈥機onnor CM (2002) A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol 39:210鈥?18PubMed View Article
2.Abraham WT, Smith SA (2013) Devices in the management of advanced, chronic heart failure. Nat Rev Cardiol 10:98鈥?10PubMed Central PubMed View Article
3.Jiang F, Yang J, Zhang Y et al (2014) Angiotensin-converting enzyme 2 and angiotensin 1鈥?: novel therapeutic targets. Nat Rev Cardiol 11:413鈥?26PubMed View Article
4.Lang CC, Struthers AD (2013) Targeting the renin-angiotensin-aldosterone system in heart failure. Nat Rev Cardiol 10:125鈥?34PubMed View Article
5.Koitabashi N, Kass DA. (2012) Reverse remodeling in heart failure[mdash]mechanisms and therapeutic opportunities. Nat Rev Cardiol 9:147鈥?57
6.Zucker IH, Xiao L, Haack KK (2014) The central renin-angiotensin system and sympathetic nerve activity in chronic heart failure. Clin Sci (Lond) 126:695鈥?06View Article
7.Cohn JN (2014) Heart failure in 2013: continue what we are doing to treat HF, but do it better. Nat Rev Cardiol 11:69鈥?0PubMed View Article
8.Wolfram JA, Donahue JK (2013) Gene therapy to treat cardiovascular disease. J Am Heart Assoc 2:e000119PubMed Central PubMed View Article
9.Menasche P (2011) Cardiac cell therapy: lessons from clinical trials. J Mol Cell Cardiol 50:258鈥?65PubMed View Article
10.Fukushima S, Sawa Y, Suzuki K (2013) Choice of cell-delivery route for successful cell transplantation therapy for the heart. Future Cardiol 9:215鈥?27PubMed View Article
11.Behfar A, Crespo-Diaz R, Terzic A, Gersh BJ (2014) Cell therapy for cardiac repair; lessons from clinical trials. Nat Rev Cardiol 11:232鈥?46PubMed View Article
12.Sanganalmath SK, Bolli R (2013) Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res 113:810鈥?34PubMed Central PubMed View Article
13.Tous E, Purcell B, Ifkovits J, Burdick J (2011) Injectable acellular hydrogels for cardiac repair. J Cardiovasc Transl Res 4:528鈥?42PubMed View Article
14.Chawengsub Y, Gauthier KM, Campbell WB (2009) Role of arachidonic acid lipoxygenase metabolites in the regulation of vascular tone. Am J Physiol Heart Circ Physiol 297:H495鈥揌507PubMed Central PubMed View Article
15.Dorris SL, Peebles RS Jr (2012) PGI2 as a regulator of inflammatory diseases. Mediators Inflamm 2012:926968PubMed Central PubMed View Article
16.Uchida T, Hazekawa M, Yoshida M, Matsumoto K, Sakai Y (2013) A novel long-acting prostacyclin agonist (ONO-1301) with an angiogenic effect: promoting synthesis of hepatocyte growth factor and increasing cyclic AMP concentration via IP-receptor signaling. J Pharmacol Sci 123:392鈥?01PubMed View Article
17.Takahashi HK, Iwagaki H, Tamura R et al (2003) Unique regulation profile of prostaglandin E1 on adhesion molecule expression and cytokine production in human peripheral blood mononuclear cells. J Pharmacol Exp Ther 307:1188鈥?195PubMed View Article
18.Takahashi HK, Iwagaki H, Tamura R et al (2005) Differential effect of prostaglandins E1 and E2 on lipopolysaccharide-induced adhesion molecule expression on human monocytes. Eur J Pharmacol 512:223鈥?30PubMed View Article
19.Takahashi HK, Iwagaki H, Mori S, Yoshino T, Tanaka N, Nishibori M (2005) Prostaglandins E1 and E2 inhibit lipopolysaccharide-induced interleukin-18 production in monocytes. Eur J Pharmacol 517:252鈥?56PubMed View Article
20.Imanishi Y, Miyagawa S, Fukushima S et al (2013) Sustained-release delivery of prostacyclin analogue enhances bone marrow-cell recruitment and yields functional benefits for acute myocardial infarction in mice. PLoS One 8:e69302PubMed Central PubMed View Article
21.Ishimaru K, Miyagawa S, Fukushima S et al (2013) Synthetic prostacyclin agonist, ONO1301, enhances endogenous myocardial repair in a hamster model of dilated cardiomyopathy: a promising regenerative therapy for the failing heart. J Thorac Cardiovasc Surg 146:1516鈥?525PubMed View Article
22.Kubota Y, Miyagawa S, Fukushima S et al (2014) Impact of cardiac support device combined with slow-release prostacyclin agonist in a canine ischemic cardiomyopathy model. J Thorac Cardiovasc Surg 147:1081鈥?087PubMed View Article
23.Shirasaka T, Miyagawa S, Fukushima S et al (2013) A slow-releasing form of prostacyclin agonist (ONO1301SR) enhances endogenous secretion of multiple cardiotherapeutic cytokines and improves cardiac function in a rapid-pacing鈥搃nduced model of canine heart failure. J Thorac Cardiovasc Surg 146:413鈥?21PubMed View Article
24.Imawaka H, Sugiyama Y (1998) Kinetic study of the hepatobiliary transport of a new prostaglandin receptor agonist. J Pharmacol Exp Ther 284:949鈥?57PubMed
25.Uchida T, Hazekawa M, Morisaki T, Yoshida M, Sakai Y (2013) Effect of antioxidants on the stability of ONO-1301, a novel long-acting prostacyclin agonist, loaded in PLGA microspheres. J Microencapsul 30:245鈥?56PubMed View Article
26.Tsai MK, Hsieh CC, Kuo HF et al (2014) Effect of prostaglandin I2 analogs on macrophage inflammatory protein 1伪 in human monocytes via I prostanoid receptor and cyclic adenosine monophosphate. J Invest Med 62:332鈥?39
27.Nakamura K, Sata M, Iwata H et al (2007) A synthetic small molecule, ONO-1301, enhances endogenous growth factor expression and augments angiogenesis in the ischaemic heart. Clin Sci (Lond) 112:607鈥?16View Article
28.Xiao CY, Yuhki KI, Hara A et al (2004) Prostaglandin E2 protects the heart from ischemia-reperfusion injury via its receptor subtype EP4. Circulation 109:2462鈥?468PubMed View Article
29.Tanaka M, Sakai A, Uchida S et al (2004) Prostaglandin E2 receptor (EP4) selective agonist (ONO-4819.CD) accelerates bone repair of femoral cortex after drill-hole injury associated with local upregulation of bone turnover in mature rats. Bone 34:940鈥?48PubMed View Article
30.Sasaoka R, Terai H, Toyoda H, Imai Y, Sugama R, Takaoka K (2004) A prostanoid receptor EP4 agonist enhances ectopic bone formation induced by recombinant human bone morphogenetic protein-2. Biochem Biophys Res Commun 318:704鈥?09PubMed View Article
31.Pagkalos J, Leonidou A, As-Sultany M, Heliotis M, Mantalaris A, Tsiridis E (2012) Prostaglandin E(2) receptors as potential bone anabolic targets鈥攕elective EP4 receptor agonists. Curr Mol Pharmacol 5:174鈥?81PubMed View Article
32.Ninomiya T, Hosoya A, Hiraga T et al (2011) Prostaglandin E(2) receptor EP(4)-selective agonist (ONO-4819) increases bone formation by modulating mesenchymal cell differentiation. Eur J Pharmacol 650:396鈥?02PubMed View Article
33.Namikawa T, Terai H, Hoshino M et al (2007) Enhancing effects of a prostaglandin EP4 receptor agonist on recombinant human bone morphogenetic protein-2 mediated spine fusion in a rabbit model. Spine (Phila Pa 1976) 32:2294鈥?299View Article
34.Nakagawa K, Imai Y, Ohta Y, Takaoka K (2007) Prostaglandin E2 EP4 agonist (ONO-4819) accelerates BMP-induced osteoblastic differentiation. Bone 41:543鈥?48PubMed View Article
35.Marui A, Hirose K, Maruyama T et al (2006) Prostaglandin E2 EP4 receptor-selective agonist facilitates sternal healing after harvesting bilateral internal thoracic arteries in diabetic rats. J Thorac Cardiovasc Surg 131:587鈥?93PubMed View Article
36.Ito M, Nakayama K, Konaka A, Sakata K, Ikeda K, Maruyama T (2006) Effects of a prostaglandin EP4 agonist, ONO-4819, and risedronate on trabecular microstructure and bone strength in mature ovariectomized rats. Bone 39:453鈥?59PubMed View Article
37.Hayashi K, Fotovati A, Ali SA, Oda K, Oida H, Naito M (2005) Prostaglandin EP4 receptor agonist augments fixation of hydroxyapatite-coated implants in a rat model of osteoporosis. J Bone Joint Surg Br 87:1150鈥?156PubMed View Article
38.Hagino H, Kuraoka M, Kameyama Y, Okano T, Teshima R (2005) Effect of a selective agonist for prostaglandin E receptor subtype EP4 (ONO-4819) on the cortical bone response to mechanical loading. Bone 36:444鈥?53PubMed View Article
39.Chang F, Mishima H, Ishii T et al (2007) Stimulation of EP4 receptor enhanced bone consolidation during distraction osteogenesis. J Orthop Res 25:221鈥?29PubMed View Article
40.Sekiguchi M, Konno SI, Kikuchi SI (2006) Effects on improvement of blood flow in the chronically compressed cauda equina: comparison between a selective prostaglandin E receptor (EP4) agonist and a prostaglandin E1 derivate. Spine 31:869鈥?72PubMed View Article
41.Kasai K, Sato SI, Suzuki K (2001) A novel prostaglandin E receptor subtype agonist, ONO-4819, attenuates acute experimental liver injury in rats. Hepatol Res 21:252鈥?60PubMed View Article
42.Honma Y, Arai I, Hashimoto Y et al (2005) Prostaglandin D2 and prostaglandin E2 accelerate the recovery of cutaneous barrier disruption induced by mechanical scratching in mice. Eur J Pharmacol 518:56鈥?2PubMed View Article
43.Nakagawa N, Yuhki KI, Kawabe JI et al (2012) The intrinsic prostaglandin E2-EP4 system of the renal tubular epithelium limits the development of tubulointerstitial fibrosis in mice. Kidney Int 82:158鈥?71PubMed View Article
44.Nakase H, Fujiyama Y, Oshitani N et al (2010) Effect of EP4 agonist (ONO-4819CD) for patients with mild to moderate ulcerative colitis refractory to 5-aminosalicylates: a randomized phase II, placebo-controlled trial. Inflamm Bowel Dis 16:731鈥?33PubMed View Article
45.Hishikari K, Suzuki JI, Ogawa M et al (2009) Pharmacological activation of the prostaglandin E2 receptor EP4 improves cardiac function after myocardial ischaemia/reperfusion injury. Cardiovasc Res 81:123鈥?32PubMed Central PubMed View Article
46.Ogawa M, Suzuki JI, Kosuge H, Takayama K, Nagai R, Isobe M (2009) The mechanism of anti-inflammatory effects of prostaglandin E2 receptor 4 activation in murine cardiac transplantation. Transplantation 87:1645鈥?653PubMed View Article
47.Ngoc PB, Suzuki J, Ogawa M et al (2011) The anti-inflammatory mechanism of prostaglandin e2 receptor 4 activation in rat experimental autoimmune myocarditis. J Cardiovasc Pharmacol 57:365鈥?72PubMed View Article
48.O鈥橣arrell FM, Attwell D (2014) A role for pericytes in coronary no-reflow. Nat Rev Cardiol 11:427鈥?32PubMed View Article
49.Dominguez-Rodriguez A, Abreu-Gonzalez P, Reiter RJ (2014) Cardioprotection and pharmacological therapies in acute myocardial infarction: challenges in the current era. World J Cardiol 6:100鈥?06PubMed Central PubMed View Article
50.Frangogiannis NG (2014) The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol 11:255鈥?65PubMed Central PubMed View Article
51.Camici PG, d鈥橝mati G, Rimoldi O. (2015) Coronary microvascular dysfunction: mechanisms and functional assessment. Nat Rev Cardiol 12:48-62
52.Giblett JP, West NEJ, Hoole SP (2014) Cardioprotection for percutaneous coronary intervention-Reperfusion quality as well as quantity. Int J Cardiol 177:786鈥?93PubMed View Article
53.Sivaraman V, Yellon DM (2014) Pharmacologic therapy that simulates conditioning for cardiac ischemic/reperfusion injury. J Cardiovasc Pharmacol Ther 19:83鈥?6PubMed View Article
54.Moukarbel GV, Ayoub CM, Abchee AB (2004) Pharmacological therapy for myocardial reperfusion injury. Curr Opin Pharmacol 4:147鈥?53PubMed View Article
55.Kloner RA, Forman MB, Gibbons RJ, Ross AM, Alexander RW, Stone GW (2006) Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur Heart J 27:2400鈥?405PubMed View Article
56.Wang X, Wei M, Kuukasj盲rvi P et al (2009) The anti-inflammatory effect of bradykinin preconditioning in coronary artery bypass grafting (bradykinin and preconditioning). Scand Cardiovasc J 43:72鈥?9PubMed View Article
57.Wong GTC, Huang Z, Ji S, Irwin MG (2010) Remifentanil reduces the release of biochemical markers of myocardial damage after coronary artery bypass surgery: a randomized trial. J Cardiothorac Vasc Anesth 24:790鈥?96PubMed View Article
58.L酶nborg J, Vejlstrup N, Kelb忙k H et al (2012) Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 33:1491鈥?499PubMed View Article
59.Kitakaze M, Asakura M, Kim J et al (2007) Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 370:1483鈥?493PubMed View Article
60.Najjar SS, Rao SV, Melloni C et al (2011) Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA 305:1863鈥?872PubMed Central PubMed View Article
61.Diaz R, Goyal A, Mehta SR et al (2007) Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction. JAMA 298:2399鈥?405PubMed View Article
62.Garcia C, Julier K, Bestmann L et al (2005) Preconditioning with sevoflurane decreases PECAM-1 expression and improves one-year cardiovascular outcome in coronary artery bypass graft surgery. Br J Anaesth 94:159鈥?65PubMed View Article
63.Yusuf S, Macmahon S, Collins R, Peto R (1998) Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials. Lancet 331:1088鈥?092View Article
64.Kim JS, Kim J, Choi D et al (2010) Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction. The STATIN STEMI trial. JACC Cardiovasc Interv 3:332鈥?39PubMed View Article
65.Mochly-Rosen D, Das K, Grimes KV (2012) Protein kinase C, an elusive therapeutic target? Nat Rev Drug Discov 11:937鈥?57PubMed Central PubMed View Article
66.Piot C, Croisille P, Staat P et al (2008) Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 359:473鈥?81PubMed View Article
67.Schwartz BG, Levine LA, Comstock G, Stecher VJ, Kloner RA (2012) Cardiac uses of phosphodiesterase-5 inhibitors. J Am Coll Cardiol 59:9鈥?5PubMed View Article
68.Fukushima S, Coppen SR, Varela-Carver A et al (2006) Enhanced efficiency of superoxide dismutase-induced cardioprotection by retrograde intracoronary administration. Cardiovasc Res 69:459鈥?65PubMed View Article
69.Fukushima S, Coppen SR, Varela-Carver A et al (2006) A novel strategy for myocardial protection by combined antibody therapy inhibiting both P-selectin and intercellular adhesion molecule-1 via retrograde intracoronary route. Circulation 114:I251鈥揑256PubMed View Article
70.Hirata Y, Shimabukuro M, Uematsu E et al (2012) A synthetic prostacyclin agonist with thromboxane synthase inhibitory activity, ONO-1301, protects myocardium from ischemia/reperfusion injury. Eur J Pharmacol 674:352鈥?58PubMed View Article
71.Iwata H, Nakamura K, Sumi M et al (2009) Local delivery of synthetic prostacycline agonist augments collateral growth and improves cardiac function in a swine chronic cardiac ischemia model. Life Sci 85:255鈥?61PubMed View Article
72.Hirata Y, Soeki T, Akaike M, Sakai Y, Igarashi T, Sata M (2009) Synthetic prostacycline agonist, ONO-1301, ameliorates left ventricular dysfunction and cardiac fibrosis in cardiomyopathic hamsters. Biomed Pharmacother 63:781鈥?86PubMed View Article
73.Suzuki JI, Ogawa M, Sakai Y, Hirata Y, Isobe M, Nagai R (2012) A prostacycline analog prevents chronic myocardial remodeling in murine cardiac allografts. Int Heart J 53:64鈥?7PubMed View Article
74.Hirata Y, Kurobe H, Uematsu E et al (2013) Beneficial effect of a synthetic prostacyclin agonist, ONO-1301, in rat autoimmune myocarditis model. Eur J Pharmacol 699:81鈥?7PubMed View Article
75.Kainuma S, Miyagawa S, Fukushima S et al (2015) Cell-sheet therapy with omentopexy promotes arteriogenesis and improves coronary circulation physiology in failing heart. Mol Ther 23:374鈥?86PubMed View Article
76.Mann DL, Kubo SH, Sabbah HN et al (2012) Beneficial effects of the CorCap cardiac support device: five-year results from the Acorn Trial. J Thorac Cardiovasc Surg 143:1036鈥?042PubMed Central PubMed View Article
77.Fukushima S, Campbell NG, Coppen SR et al (2011) Quantitative assessment of initial retention of bone marrow mononuclear cells injected into the coronary arteries. J Heart Lung Transplant 30:227鈥?33PubMed View Article
78.Fukushima S, Varela-Carver A, Coppen SR et al (2007) Direct intramyocardial but not intracoronary injection of bone marrow cells induces ventricular arrhythmias in a rat chronic ischemic heart failure model. Circulation 115:2254鈥?261PubMed View Article
79.Miyagawa S, Saito A, Sakaguchi T et al (2010) Impaired myocardium regeneration with skeletal cell sheets鈥攁 preclinical trial for tissue-engineered regeneration therapy. Transplantation 90:364鈥?72PubMed View Article
80.Shudo Y, Miyagawa S, Fukushima S et al (2011) Novel regenerative therapy using cell-sheet covered with omentum flap delivers a huge number of cells in a porcine myocardial infarction model. J Thorac Cardiovasc Surg 142:1188鈥?196PubMed View Article
81.Zamanian RT, Kudelko KT, Sung YK, de Jesus Perez V, Liu J, Spiekerkoetter E (2014) Current clinical management of pulmonary arterial hypertension. Circ Res 115:131鈥?47PubMed View Article
82.Ruan CH, Dixon RA, Willerson JT, Ruan KH (2010) Prostacyclin therapy for pulmonary arterial hypertension. Tex Heart Inst J 37:391鈥?99PubMed Central PubMed
83.Kataoka M, Nagaya N, Satoh T et al (2005) A long-acting prostacyclin agonist with thromboxane inhibitory activity for pulmonary hypertension. Am J Respir Crit Care Med 172:1575鈥?580PubMed View Article
84.Antoniu SA (2006) Non-prostanoid prostacyclin agonists for the treatment of pulmonary arterial hypertension. Expert Opin Investig Drugs 15:327鈥?30PubMed View Article
85.Obata H, Sakai Y, Ohnishi S et al (2008) Single injection of a sustained-release prostacyclin analog improves pulmonary hypertension in rats. Am J Respir Crit Care Med 177:195鈥?01PubMed View Article
86.Nakamura A, Nagaya N, Obata H et al (2013) Oral administration of a novel long-acting prostacyclin agonist with thromboxane synthase inhibitory activity for pulmonary arterial hypertension. Circ J 77:2127鈥?133PubMed View Article
87.Murakami S, Nagaya N, Itoh T et al (2006) Prostacyclin agonist with thromboxane synthase inhibitory activity (ONO-1301) attenuates bleomycin-induced pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol 290:L59鈥揕65PubMed View Article
88.Hayashi M, Koya T, Kawakami H et al (2010) A prostacyclin agonist with thromboxane inhibitory activity for airway allergic inflammation in mice. Clin Exp Allergy 40:317鈥?26PubMed View Article
89.Kimura Y, Koya T, Kagamu H et al (2013) A single injection of a sustained-release prostacyclin analog (ONO-1301MS) suppresses airway inflammation and remodeling in a chronic house dust mite-induced asthma model. Eur J Pharmacol 721:80鈥?5PubMed View Article
90.Hayashi K, Nagamatsu T, Oka T, Suzuki Y (1997) Modulation of anti-glomerular basement membrane nephritis in rats by ONO-1301, a non-prostanoid prostaglandin I2 mimetic compound with inhibitory activity against thromboxane A2 synthase. Jpn J Pharmacol 73:73鈥?2PubMed View Article
91.Yamasaki H, Maeshima Y, Nasu T et al (2011) Intermittent administration of a sustained-release prostacyclin analog ONO-1301 ameliorates renal alterations in a rat type 1 diabetes model. Prostaglandins Leukot Essent Fatty Acids 84:99鈥?07PubMed View Article
92.Nasu T, Kinomura M, Tanabe K et al (2012) Sustained-release prostacyclin analog ONO-1301 ameliorates tubulointerstitial alterations in a mouse obstructive nephropathy model. Am J Physiol Renal Physiol 302:F1616鈥揊1629PubMed View Article
93.Hazekawa M, Sakai Y, Yoshida M, Haraguchi T, Uchida T (2012) The effect of treatment with a sustained-release prostacyclin analogue (ONO-1301-loaded PLGA microsphere) on short-term memory impairment in rats with transient global cerebral ischemia. J Microencapsul 29:211鈥?18PubMed View Article
94.Hazekawa M, Sakai Y, Yoshida M, Haraguchi T, Uchida T (2012) Single injection of ONO-1301-loaded PLGA microspheres directly after ischaemia reduces ischaemic damage in rats subjected to middle cerebral artery occlusion. J Pharm Pharmacol 64:353鈥?59PubMed View Article
95.Xu Q, Nakayama M, Suzuki Y et al (2012) Suppression of acute hepatic injury by a synthetic prostacyclin agonist through hepatocyte growth factor expression. Am J Physiol Gastrointest Liver Physiol 302:G420鈥揋429PubMed View Article
96.Xu Q, Sakai K, Suzuki Y, Tambo C, Sakai Y, Matsumoto K (2013) Suppression of fibrogenic gene expression and liver fibrosis using a synthetic prostacyclin agonist. Biomed Res 34:241鈥?50PubMed View Article
97.Niina Y, Ito T, Oono T et al (2014) A sustained prostacyclin analog, ONO-1301, attenuates pancreatic fibrosis in experimental chronic pancreatitis induced by dibutyltin dichloride in rats. Pancreatology 14:201鈥?10PubMed View Article
98.Lederle FA, Freischlag JA, Kyriakides TC et al (2012) Long-term comparison of endovascular and open repair of abdominal aortic aneurysm. N Engl J Med 367:1988鈥?997PubMed View Article
99.Malina M, Brunkwall J, Ivancev K, J枚nsson J, Malina J, Lindblad B (2000) Endovascular healing is inadequate for fixation of dacron stent-grafts in human aortoiliac vessels. Eur J Vasc Endovasc Surg 19:5鈥?1PubMed View Article
100.Watanabe Y, Miyagawa S, Fukushima S et al (2014) Development of a prostacyclin-agonist鈥揺luting aortic stent graft enhancing biological attachment to the aortic wall. J Thorac Cardiovasc Surg 148(2325鈥?4):e1PubMed
101.Agarwal S, Tuzcu EM, Krishnaswamy A et al (2015) Transcatheter aortic valve replacement: current perspectives and future implications. Heart 101:169鈥?77PubMed View Article - 作者单位：Satsuki Fukushima (1)
Shigeru Miyagawa (1)
Yoshiki Sakai (1)
Yoshiki Sawa (1)
1. Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan - 刊物类别：Medicine
- 刊物主题：Medicine & Public Health
Cardiology - 出版者：Springer Netherlands
- ISSN：1573-7322
文摘
Cardiac failure is a major cause of mortality and morbidity worldwide, since the standard treatment for cardiac failure in the clinical practice is chiefly to focus on removal of insults against the heart or minimisation of additional factors to exacerbate cardiac failure, but not on regeneration of the damaged cardiac tissue. A synthetic prostacyclin agonist, ONO-1301, has been developed as a long-acting drug for acute and chronic pathologies related to regional ischaemia, inflammation and/or interstitial fibrosis by pre-clinical studies. In addition, poly-lactic co-glycolic acid-polymerised form of ONO-1301, ONO-1301SR, was generated to achieve a further sustained release of this drug into the targeted region. This unique reagent has been shown to act on fibroblasts, vascular smooth muscle cells and endothelial cells in the tissue via the prostaglandin IP receptor to exert paracrinal release of multiple protective factors, such as hepatocyte growth factor, vascular endothelial growth factor or stromal cell-derived factor-1, into the adjacent damaged tissue, which is salvaged and/or regenerated as a result. Our laboratory developed a new surgical approach to treat acute and chronic cardiac failure using a variety of animal models, in which ONO-1301SR is directly placed over the cardiac surface to maximise the therapeutic effects and minimise the systemic complications. This review summarises basic and pre-clinical information of ONO-1301 and ONO-1301SR as a new reagent to enhance tissue salvage and/or regeneration, with a particular focus on the therapeutic effects on acute and chronic cardiac failure and underlying mechanisms, to explore a potential in launching the clinical study.